New targeted drug plus chemo for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II, III, or IV ovarian, fallopian tube, or primary peritoneal cancer (confirmed by a biopsy).
- You had surgery to remove the tumor before any chemotherapy, and the surgeon was able to remove most or all visible cancer (R0 or R1).
- Your tumor has high levels of a protein called HER2 (IHC 2+ or 3+).
- You have not had any chemotherapy yet for this cancer.
- You are generally active and able to take care of yourself (ECOG score 0–2).
- Your heart, blood counts, liver, and kidney function are working well enough (based on blood tests and heart scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.